Free tool
FAERS Monitor: Povidone Iodine
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019522 or its brand name (Povidone Iodine, Povidone-Iodine). Reports on generic versions are filed under their own applications.
Reports
2,059
Serious
1,932
94% of reports
Hospitalization
772
Death reported
361
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use320
- endophthalmitis229
- drug ineffective191
- nausea191
- rash187
- pain176
- drug hypersensitivity166
- product use in unapproved indication144
- confusional state142
- rheumatoid arthritis142
- pericarditis137
- wound135
- type 2 diabetes mellitus134
- c-reactive protein increased133
- pemphigus132
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 55 |
| 2005 | 27 |
| 2006 | 35 |
| 2007 | 51 |
| 2008 | 59 |
| 2009 | 53 |
| 2010 | 59 |
| 2011 | 73 |
| 2012 | 85 |
| 2013 | 49 |
| 2014 | 53 |
| 2015 | 41 |
| 2016 | 66 |
| 2017 | 120 |
| 2018 | 109 |
| 2019 | 193 |
| 2020 | 104 |
| 2021 | 55 |
| 2022 | 169 |
| 2023 | 106 |
| 2024 | 142 |
| 2025 | 216 |
| 2026 | 139 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,100 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| endophthalmitisSignal | 229 | 405.4 | 357.8 | 88,485 |
| pemphigusSignal | 132 | 109.0 | 92.3 | 13,878 |
| pericarditisSignal | 137 | 84.0 | 71.4 | 11,068 |
| woundSignal | 135 | 49.6 | 42.1 | 6,354 |
| type 2 diabetes mellitusSignal | 134 | 40.8 | 34.6 | 5,153 |
| c-reactive protein increasedSignal | 133 | 37.5 | 31.8 | 4,676 |
| rheumatoid arthritisSignal | 142 | 12.8 | 10.9 | 1,538 |
| confusional stateSignal | 142 | 9.0 | 7.7 | 1,006 |
| drug hypersensitivitySignal | 166 | 8.8 | 7.6 | 1,144 |
| product use in unapproved indicationSignal | 144 | 5.9 | 5.1 | 593 |
| rashSignal | 187 | 4.4 | 3.8 | 495 |
| off label useSignal | 320 | 3.7 | 3.4 | 665 |
| painSignal | 176 | 2.9 | 2.5 | 228 |
| nauseaSignal | 191 | 2.5 | 2.2 | 171 |
| drug ineffective | 191 | 1.5 | 1.3 | 31 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.